CO2017007123A2 - Anticuerpos biespecíficos contra calicreína y factor xii del plasma - Google Patents

Anticuerpos biespecíficos contra calicreína y factor xii del plasma

Info

Publication number
CO2017007123A2
CO2017007123A2 CONC2017/0007123A CO2017007123A CO2017007123A2 CO 2017007123 A2 CO2017007123 A2 CO 2017007123A2 CO 2017007123 A CO2017007123 A CO 2017007123A CO 2017007123 A2 CO2017007123 A2 CO 2017007123A2
Authority
CO
Colombia
Prior art keywords
light chain
factor xii
heavy chain
bispecific antibodies
kallikrein
Prior art date
Application number
CONC2017/0007123A
Other languages
English (en)
Spanish (es)
Inventor
Burt Adelman
Andrew Nixon
Niksa Kastrapeli
Shauna Mason
Kristopher Kopacz
Gregory P Conley
Stephen R Comeau
Jon A Kenniston
Allison P Lindberg
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CO2017007123A2 publication Critical patent/CO2017007123A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CONC2017/0007123A 2015-01-02 2017-07-17 Anticuerpos biespecíficos contra calicreína y factor xii del plasma CO2017007123A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US201562261609P 2015-12-01 2015-12-01
PCT/US2015/068238 WO2016109774A1 (en) 2015-01-02 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii

Publications (1)

Publication Number Publication Date
CO2017007123A2 true CO2017007123A2 (es) 2017-12-15

Family

ID=56285069

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007123A CO2017007123A2 (es) 2015-01-02 2017-07-17 Anticuerpos biespecíficos contra calicreína y factor xii del plasma

Country Status (13)

Country Link
US (2) US11390687B2 (enExample)
EP (1) EP3240570B1 (enExample)
JP (4) JP6744313B2 (enExample)
KR (2) KR20240091031A (enExample)
CN (2) CN107405399B (enExample)
AU (2) AU2015373910B2 (enExample)
CA (1) CA2972800A1 (enExample)
CO (1) CO2017007123A2 (enExample)
EA (1) EA201791527A1 (enExample)
IL (2) IL298086B2 (enExample)
MX (2) MX2017008541A (enExample)
NZ (1) NZ771568A (enExample)
WO (1) WO2016109774A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
US10913802B2 (en) * 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
JP7319916B2 (ja) 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のｒｎａバイオマーカー
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN111065649A (zh) * 2017-08-16 2020-04-24 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质
CA3079568A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
CN119291194A (zh) * 2018-01-12 2025-01-10 建新公司 用于定量多肽的方法
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008684A (es) * 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
BR112020024992A2 (pt) * 2018-06-08 2021-03-23 Modalis Therapeutics Corporation proteína cas9 modificada e uso da mesma
BR112021000383A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1
MX2021001527A (es) * 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
BR112021002278A2 (pt) * 2018-08-08 2021-07-20 Dragonfly Therapeutics, Inc. proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor
CA3114803A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
PH12022550195A1 (en) 2019-07-26 2022-11-21 Janssen Biotech Inc Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
WO2022156799A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101260156A (zh) * 2002-06-28 2008-09-10 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US8119137B2 (en) 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
KR102107695B1 (ko) * 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
PT2734552T (pt) 2011-07-22 2025-01-29 Csl Behring Gmbh Anticorpos monoclonais inibidores do fator xii/xiia e suas utilizações
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
EP3617313A1 (en) * 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
ES2698950T3 (es) 2012-05-10 2019-02-06 Bayer Pharma AG Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos
US20140038204A1 (en) * 2012-07-31 2014-02-06 Baxter Healthcare S.A. Selective measurement of active human protease coagulation factors
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
LT2946206T (lt) 2013-01-20 2019-04-25 Dyax Corp. Pkal sąlygotų sutrikimų vertinimas, tyrimas ir gydymas
AU2014240045A1 (en) * 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
PL3013366T3 (pl) * 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Also Published As

Publication number Publication date
MX2024000317A (es) 2024-01-25
EP3240570C0 (en) 2025-09-24
EP3240570A1 (en) 2017-11-08
CN114316061B (zh) 2024-11-01
IL253180A0 (en) 2017-08-31
CN114316061A (zh) 2022-04-12
JP6744313B2 (ja) 2020-08-26
IL253180B2 (en) 2023-04-01
KR20170118058A (ko) 2017-10-24
IL298086B2 (en) 2024-11-01
IL298086B1 (en) 2024-07-01
IL253180B (en) 2022-12-01
NZ771568A (en) 2024-11-29
JP2023065659A (ja) 2023-05-12
MX2017008541A (es) 2017-12-04
AU2022201076A1 (en) 2022-03-10
AU2015373910B2 (en) 2021-11-18
KR20240091031A (ko) 2024-06-21
JP2020186248A (ja) 2020-11-19
US11390687B2 (en) 2022-07-19
NZ733580A (en) 2024-02-23
EP3240570A4 (en) 2018-08-08
AU2015373910A1 (en) 2017-07-27
CN107405399B (zh) 2022-02-08
JP7003347B2 (ja) 2022-02-04
IL298086A (en) 2023-01-01
JP7241827B2 (ja) 2023-03-17
EA201791527A1 (ru) 2017-12-29
AU2022201076B2 (en) 2025-05-15
EP3240570B1 (en) 2025-09-24
US20180118851A1 (en) 2018-05-03
JP7635285B2 (ja) 2025-02-25
CA2972800A1 (en) 2016-07-07
US20230117565A1 (en) 2023-04-20
CN107405399A (zh) 2017-11-28
JP2018502572A (ja) 2018-02-01
US12240918B2 (en) 2025-03-04
KR102670705B1 (ko) 2024-05-31
JP2022023038A (ja) 2022-02-07
WO2016109774A1 (en) 2016-07-07
BR112017014308A2 (pt) 2018-03-06

Similar Documents

Publication Publication Date Title
CO2017007123A2 (es) Anticuerpos biespecíficos contra calicreína y factor xii del plasma
UY36194A (es) Anticuerpos anti-tau humanizados
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
CL2019001352A1 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo.
MX2018012468A (es) Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CU24568B1 (es) Anticuerpo inhibidor de masp-3
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
MX377716B (es) Moduladores de aplnr y usos de estos.
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
EA033403B1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
CO2018001599A2 (es) Un inhibidor de anticuerpo monoclonal de factor xiia
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
CO2018010286A2 (es) Método para la purificación de proteínas
EA201591279A1 (ru) Новые фрагменты антител, их композиции и способы применения
MX389687B (es) Inmunoglobulinas conjugadas en cys80.
BR112017025264A2 (pt) tratamento de prurido
MX386543B (es) Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
AR101185A1 (es) Anticuerpos anti-factor v o factor v activado